The Joint Committee on Immunization and Immunization (JCVI) responded to the emergence of Omicron variants, updated its guidance and took effect immediately.
According to a JCVI statement, high-level antibodies induced by vaccines directed at the original “wild-type” mutants are the Omicron mutants, as demonstrated by laboratory studies of other mutants. May provide better protection against. Research is underway nationally and internationally to determine the validity of this claim.
JCVI advises on the following emergency measures within the COVID-19 vaccine program:
- Eligibility for booster vaccination should be expanded to include all adults between the ages of 18 and 39.
- Booster vaccination should be provided in descending order of age group, with priority given to vaccination of the elderly and the COVID-19 risk group. Booster vaccination should not occur within 3 months of the completion of the primary course.
- Patients with severe immunosuppression who have completed the first course (three doses) should be provided with a booster dose of at least three months between the third primary dose and the booster dose. Those who have not yet received a third dose can now take a third dose to avoid further delays. Additional boosters can be given within 3 months, following clinical advice on optimal timing.
- Both the Moderna vaccine and the Pfizer-BioNTech vaccine should be used with equal priority in the COVID-19 booster program. Both vaccines have been shown to substantially increase antibody levels when delivered as a boosted immune dose.
In addition, JCVI advises on the following secondary measures, subject to appropriate consideration by the deployment team regarding feasibility.
All children and adolescents aged 12 to 15 years should be provided with a second dose (30 micrograms) of the Pfizer-BioNTech COVID-19 vaccine at least 12 weeks after the first dose. If new epidemiological data support this, the vaccine interval can be reduced to at least 8 weeks at the dosing interval (if 16-17 year olds are also offered a second dose at least 8 weeks apart). there is).
The overall intent of the above measures is to accelerate the deployment of the COVID-19 vaccine before the imminent wave peak due to the Omicron mutation. Currently, there are no data showing that Omicron infection is associated with altered patterns of susceptibility to severe COVID-19 (hospitalization and death). Elderly people, or those who belong to a group at risk for COVID-19, may remain at high risk for severe COVID-19. Therefore, vaccination should be prioritized accordingly.
Dr. June Raine, Chief Executive Officer of MHRA, said: This will protect people from COVID-19 and allow them to save lives.
“Our safety surveillance to date has shown that the COVID-19 vaccine remains safe and effective for the majority of people. Most of the reported reactions are in the initial assessment. As seen, it is associated with possible side effects such as injection site reactions and flu-like symptoms. Active monitoring of booster dose safety raises no new concerns.
“We continue to carefully scrutinize all available data, and our powerful monitoring program includes monitoring of all suspicious reactions in adolescents, adolescents, and adults. Suspicious reports Everything is carefully followed up. When booster effects are sought, you can be confident that the benefits of preventing serious COVID-19 far outweigh the risks. “
JCVI responds to Omicron variants and updates guidance
Source link JCVI responds to Omicron variants and updates guidance